One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Europe Genetic Testing Market

[ 英語タイトル ] Europe Genetic Testing Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0088841
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 84
Category : Healthcare and Pharmaceuticals
Study Area : Europe
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3750 / Question Form
5 User USD4250 / Question Form
Enterprise User USD7000 / Question Form
 - Illumina Inc.
- Abbott Laboratories
- 23andMe Inc.
- F. Hoffmann-La Roche Ltd
- Qiagen
- Blueprint Genetics Oy
- Eurofins Scientific
- Centogene AG
- Thermo Fisher Scientific
- Elitech Group

[Report Description]

Genetic testing has been growing at an unprecedented rate; a large panel of tests are now available to screen a number of genetic diseases. Treatment is available for a number of rare genetic diseases and the procedure is gaining importance in scenarios, such as carrier testing, newborn screening, predictive and pre-symptomatic testing, etc.

- Technologies, such as next-generation sequencing, allow to carry out many genetic tests rapidly and create databases with information about rare genetic diseases. The European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing.
- There are a number of favorable and collaborative policies that are being implemented by the governments to incorporate genetic testing into the healthcare system and to make insurance reimbursements available to citizens. Cancer genetic testing, Alzheimer’s disease testing, and cystic fibrosis testing are the most popular screening tests being carried out in Europe. Others include hereditary breast cancer and ovarian cancer syndromes, Li-Fraumeni syndrome, Cowden syndrome, Lynch syndrome, Familial adenomatous polyposis, and retinoblastoma, among others.
- The practice of genetic testing for hereditary cancer syndromes has changed dramatically in the recent years. In developed countries, like Germany, France, etc., the demand for genetic testing to detect cancer risks is driving the growth of the market. The high GDP expenditure on healthcare, per capita expenditure, increase in awareness among the people, and high income of the citizens are the factors that drive the market in European countries.

Key Market Trends

The Diagnostic Testing Segment is Expected to Grow the Fastest over the Forecast Period

Diagnostics testing is expected to register a healthy CAGR, as it is used to diagnose or rule out a specific genetic condition. This is attributable to the growth in awareness among people regarding health and the increase in incidences of mortality rate due to the genetic diseases in the region. In most cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical mutations and symptoms. Therefore, the increasing conditions like, cancer, Alzheimer’s disease, and cystic fibrosis, boost the segment’s growth. Furthermore, companies, such as Centogene and NIMGenetics, offer a wide range of genetic diagnostic services in Europe, which is further accelerating the growth of the market.

Competitive Landscape

The European genetic testing market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Increasing Demand for Personalized Medicine
4.2.3 Increasing Application of Genetic Testing in Oncology
4.3 Market Restraints
4.3.1 High Costs of Genetic Testing
4.3.2 Social and Ethical Implications of Genetic Testing
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Newborn Screening
5.1.4 Predictive and Presymptomatic Testing
5.1.5 Prenatal Testing
5.1.6 Other Types
5.2 By Disease
5.2.1 Alzheimer's Disease
5.2.2 Cancer
5.2.3 Cystic Fibrosis
5.2.4 Sickle Cell Anemia
5.2.5 Duchenne Muscular Dystrophy
5.2.6 Thalassemia
5.2.7 Huntington's Disease
5.2.8 Other Diseases
5.3 By Technology
5.3.1 Cytogenetic Testing
5.3.2 Biochemical Testing
5.3.3 Molecular Testing
5.4 Geography
5.4.1 Europe Germany United Kingdom France Italy Spain Rest of Europe

6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 Abbott Laboratories
6.1.3 23andMe Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Qiagen
6.1.6 Blueprint Genetics Oy
6.1.7 Eurofins Scientific
6.1.8 Centogene AG
6.1.9 Thermo Fisher Scientific
6.1.10 Elitech Group




Recommended reports